Accessibility Menu
 

Why the Future Is Bright for Isis Pharmaceuticals

Isis' collaboration with Biogen and AstraZeneca have resulted in two new phase 1 drug prospects as one drug for diabetic macular edema fails.

By Todd Campbell Jun 10, 2014 at 6:30PM EST

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.